Ed Arce
Stock Analyst at WestPark Capital
(4.23)
# 457
Out of 5,128 analysts
406
Total ratings
46.01%
Success rate
17.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $13.89 | +101.58% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $36.28 | -17.31% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $8.77 | +1,405.13% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $6.01 | +1,147.92% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $6.84 | +777.19% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.53 | +390.20% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $5.10 | +154.90% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $3.54 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $1.26 | +376.19% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $9.65 | +625.39% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $31.39 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $2.91 | +8,147.42% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.35 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $5.52 | +479.71% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $221.38 | -84.19% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $81.98 | -12.17% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $561.13 | -27.82% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $5.83 | -5.66% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $24.20 | +292.56% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.88 | +2.46% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $35.45 | +35.40% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $40.00 | -81.25% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.36 | +1,292.76% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $16.02 | -18.85% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.18 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $48.68 | -48.64% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.83 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.01 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $32.38 | -78.38% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $47.23 | -55.54% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.48 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $13.89
Upside: +101.58%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $36.28
Upside: -17.31%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $8.77
Upside: +1,405.13%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $6.01
Upside: +1,147.92%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $6.84
Upside: +777.19%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.53
Upside: +390.20%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $5.10
Upside: +154.90%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $3.54
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $1.26
Upside: +376.19%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $9.65
Upside: +625.39%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $31.39
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $2.91
Upside: +8,147.42%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $5.52
Upside: +479.71%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $221.38
Upside: -84.19%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $81.98
Upside: -12.17%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $561.13
Upside: -27.82%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $5.83
Upside: -5.66%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $24.20
Upside: +292.56%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.88
Upside: +2.46%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $35.45
Upside: +35.40%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $40.00
Upside: -81.25%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.36
Upside: +1,292.76%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $16.02
Upside: -18.85%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.18
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $48.68
Upside: -48.64%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.83
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $19.01
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $32.38
Upside: -78.38%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $47.23
Upside: -55.54%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.48
Upside: -